Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Share-based compensation expense

Asset impairment and restructuring costs

Expected credit losses on financial assets and related charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Canopy Growth

Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Marquee Raine Acquisition Corp.

Martha Stewart CBD on Wednesday unveiled a line of CBD edibles offering aid in sleep and other potential wellness benefits, with backing from Canopy Growth Corp. CGC CA:WEED as well as Marquee Brands, a licensing and development company backed by Neuberger Berman Private Equity. Martha Stewart's Sleep CBD Gummies sell for a suggested retail price of $59.99 for 60 gummies containing 25 milligrams of CBD and 3 milligrams of melatonin.

Martha Stewart launches CBD line with backing from Canopy Growth, Marquee Brands

Cronos Group

OrganiGram Holdings Inc.

In an August 2023 column, I wrote “With the chances of marijuana companies accessing the U.S. financial system higher than ever and cannabis stocks trading at lower valuations than ever before, now looks like an excellent time to seek out top-notch cannabis stocks to buy.” I also identified three cannabis companies with very attractive valuations and strong outlooks.

3 Underperforming Cannabis Stocks You Better Not Be Buying

Ohio just advanced the legalization of recreational cannabis use. Canopy Growth can't enter the new market directly, at least not for now.

With More States Voting to Legalize Marijuana, Is Canopy Growth Stock a Buy?

Aurora Cannabis

Curaleaf Holdings, Inc.

An end to federal prohibition may be in reach, according to Senate Majority Leader Chuck Schumer. All thanks to bipartisan legislation that could give the industry access to banking services.

3 Marijuana Penny Stocks to Buy Before the Cannabis Crazes Ignites Again

SNDL Inc.

Tilray Brands

Investing in marijuana stocks has gained traction for several compelling reasons. First off, the evolving legal landscape is opening up new markets, especially in regions where regulations are becoming more cannabis-friendly. The cannabis industry spans from medicinal to recreational use. Which is all poised for significant growth, and has attracted more people seeking to diversify their portfolios.

3 Canadian Marijuana Stocks Investors Continue To Watch

Canopy Growth Corp.'s stock CGC, -2.23% WEED, -1.33% was up 1.7% in premarket trading on Friday after the Canadian cannabis company said it identified two qualified buyers for its BioSteel brand and assets. The anticipated proceeds of the deals are expected to improve its balance sheet upon completion, the company said.

Canopy Growth's stock rises after it says it's found buyers for BioSteel sports drink units

Court approves combination of transactions resulting in the sale of all or substantially all of the assets of Biosteel Canada and Biosteel Manufacturing Elimination of funding obligation to BioSteel consistent with Canopy Growth's cannabis focus and transformation to a simplified, asset-light operating model. SMITHS FALLS, ON , Nov. 17, 2023 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) today provided an update that pursuant to the proceedings under the Companies' Creditors Arrangement Act (the "CCAA") involving BioSteel Sports Nutrition Inc. ("BioSteel Canada"), the Ontario Superior Court of Justice (Commercial List) ("CCAA Court") has approved two transactions to sell all or substantially all of the assets of BioSteel Canada and BioSteel Manufacturing, LLC ("BioSteel Manufacturing") and that pending the closing of the transactions, Canopy Growth expects to realize proceeds which will improve the Company's balance sheet.

Canopy Growth Announces that BioSteel Obtains Court Approval of Successful Bids in Sale and Investment Solicitation Process

By most accounts, Canada's experiment with legalizing cannabis has been a complete failure. Five years after the recreational drug was legalized on a national level, most cannabis producers remain deeply unprofitable, struggling to survive, seeing their share prices plunge by more than 90%.

The 3 Most Undervalued Cannabis Stocks to Buy: November 2023

Canopy Growth Corp. has hit a snag with the Securities and Exchange Commission in its plan to maintain its dual listing on the Nasdaq and the Toronto Stock Exchange when it creates Canopy USA to hold potential ownership positions in U.S. cannabis businesses.

Canopy Growth hits snag with SEC over Canopy USA plan

Canopy Growth has been slashing costs, but the business remains unprofitable. Its biggest backer, Constellation Brands, looks to be distancing itself from the cannabis producer.

Canopy Growth's Stock Likely Hasn't Bottomed Out Just Yet

Benchmark analysts on Monday reiterated their sell rating on Canopy Growth Corp. as it burns cash at a rate that's more “intense than a midnight blaze” while TD Cowen sounded a more positive tone on improved gross margins at the Canadian cannabis company.

Canopy Growth's cash burn raises analyst concerns

Quarterly results from the U.S.'s largest cannabis company Curaleaf Holdings Inc. and Canada's Canopy Growth Corp. missed analyst estimates, while Ascend Wellness managed to beat forecasts.

Curaleaf and Canopy Growth miss Q3 analyst marks while Ascend Wellness beats forecasts

Canopy Growth Corporation (TSX:WEED, NYSE:CGC) after Thursday's close announced that its second quarter 2024 adjusted core loss improved to C$11.9 million from a loss of C$56.4 million a year earlier, after the Canadian cannabis company reduced its costs by an additional C$54 million during the quarter.  Its operating expenses for the period fell nearly 80% to C$30.43 million and the company has eliminated C$226 million in costs since the beginning of fiscal year 2023.

Canopy Growth sees smaller 2Q loss as revenue slide continues

Canopy Growth Corporation (NASDAQ:CGC ) Q2 2024 Results Conference Call November 9, 2023 5:30 PM ET Company Participants Tyler Burns - Director, IR David Klein - CEO Judy Hong - CFO Conference Call Participants Aaron Grey - Alliance Global Partners John Zamparo - CIBC Michael Lavery - Piper Sandler Operator Good afternoon. My name is Jovel and I will be your conference operator today.

Canopy Growth Corporation (CGC) Q2 2024 Earnings Call Transcript

Strong execution drove significant improvement in gross margins and reduced cash burn in Q2 FY2024 Management reaffirms expectation to achieve positive Adjusted EBITDA in all business units exiting FY2024 Solidified foundation expected to deliver profitable growth and achieve sustainable cannabis market leadership SMITHS FALLS, ON , Nov. 9, 2023 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announces its financial results for the second quarter ended September 30, 2023. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Canopy Growth Reports Second Quarter Fiscal Year 2024 Financial Results

Canopy Growth has been trimming costs as it shifts towards an "asset-light" operating model. Tilray has been acquiring beverage companies and brands in an effort to further diversify its operations.

Tilray Brands vs. Canopy Growth: Which Cannabis Company Has the Better Long-Term Strategy?

Village Farms International

The cannabis industry in Canada continues to be a hub of financial opportunities, drawing in both seasoned investors and novices. The industry's unrelenting expansion has been nothing short of extraordinary, driven by rising legality and soaring demand. Since cannabis was first legalized for recreational use in 2018, Canada's cannabis market has advanced significantly. Its booming retail sector, elite cultivators, and well-established infrastructure all contribute to its continued success. Growing exports abroad have also helped the industry, establishing Canada as a major cannabis-producing hub.

Top Canadian Cannabis Stocks For Q4 2023

Jazz Pharmaceuticals

MedMen Enterprises Inc.

AdvisorShares Pure Cannabis ETF 

The rollercoaster ride of the cannabis market has left many in the investing world dazed and confused. The sector's volatility is marked by winds of optimism followed by spells of disappointment.

Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now.

Canopy Growth's lack of progress with improving its free cash burn forms a core headwind to its prospects as a public company. CGC's cash position is declining as avenues to raise cash, whilst still being tapped, look increasingly exhausted. An everything rally could be sparked by a dovish Fed pivot to set the commons up for a recovery.

Canopy Growth: The Cannabis Nightmare Looks For An End

Cannabis companies are preparing to release their 2023 third-quarter earnings. If companies can show positive results we may see one final rebound before the start of 2024. In the past when people saw that companies were profitable and showing continuous success it gave them more reason to invest. In 2024 many feel that we will see another turning point for the cannabis industry. For example, we could see more states legalize cannabis. As well companies that entered into strategic partnerships in 2023 could begin to execute various business projects this new year.

Cannabis Investing 2024: Top Marijuana Stocks For You

The current cannabis trends affecting the market are likely to continue to impact the sector in 2024. First, the legal environment appears to be becoming more friendly to the drug.

3 Trends in Cannabis Stocks to Watch for 2024

Canopy Growth's hopes hinge on federal marijuana legalization in the U.S. Federal legalization could still be years away, and there's no guarantee that it ever will happen. Canopy Growth continues to burn cash at a high rate.

Down 98% in 5 Years, Is There Any Hope Canopy Growth Stock Can Ever Recover?

SMITHS FALLS, ON , Oct. 26, 2023 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) will release its financial results for the second quarter fiscal year 2024 ended September 30, 2023 after markets close on November 9, 2023. Following the release of its second quarter fiscal year 2024 financial results, Canopy Growth will host an audio webcast with David Klein, CEO and Judy Hong, CFO on November 9, at 5:30 PM Eastern Time.

Canopy Growth to Report Second Quarter Fiscal 2024 Financial Results on November 9, 2023

In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.

What's in Store for Canopy Growth (CGC) in Q2 Earnings?

Investors and traders in the Canadian cannabis market are closely monitoring the leading Canadian cannabis stocks as November draws near. Recent years have seen a substantial increase in the legalization of cannabis and a shift in public perception of the plant as a whole. New Frontier Data estimated that the global legal cannabis business was worth $17.5 billion in 2019 and that it would be worth a staggering $105.9 billion by 2025. Due to this rapid expansion and Canada's dominant position in the production and distribution of cannabis, Canadian cannabis stocks are in high demand from both long-term investors and short-term traders.

News for Canopy Growth Stock (CGC)